000756 Shandong Xinhua Pharmaceutical
- 17.35
- +0.78+4.71%
Shandong Xinhua Pharmaceutical News
Xinhua Pharmaceutical (000756.SZ): The company is an important global supplier of antipyretic and analgesic drugs
Gelonghui, May 7 | Xinhua Pharmaceutical (000756.SZ) said on the investor interactive platform that the company is an important global supplier of antipyretic and analgesic drugs and is an important domestic manufacturer of cardiovascular, anti-infective and central nervous system drugs. The company has core competitiveness such as outstanding scale advantages, obvious supporting advantages, and leading technical and economic indicators, and has a high position and influence in the domestic pharmaceutical industry. The company is one of the top 100 enterprises in the national pharmaceutical industry, the top five exporters of APIs, and the top ten pharmaceutical exporters. Has aspirin, ibuprofen, levodopa, ethoxyphenyllamine, triphenyldiamidine, marlinzin, and pyrimidine
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Net profit of 142 million yuan in the first quarter decreased by 6.41% year-on-year
Gelonghui, April 25丨Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced unaudited results for the first quarter of 2024, achieving operating income of 2,475 billion yuan, a year-on-year decrease of 6.25%; net profit attributable to shareholders of listed companies of 142 million yuan, a year-on-year decrease of 6.41%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 138 million yuan, a year-on-year decrease of 6.41%; and basic earnings per share of 0.21 yuan.
山東新華製藥股份：2024年第一季度未經審核的業績
Zhitong Hong Kong Stock Investment Calendar | April 25
According to Zhitong Finance App statistics, on April 25, 2024, the investment logs of Hong Kong stock listed companies are as follows: Category: Company Performance Announcement Sun Xintian Green Energy Era Electric Dexin China China Aluminum Sanbao Technology Tiger Pharmaceuticals China Shipbuilding Defense Shandong Xinhua Pharmaceutical Co., Ltd. Gloria Ying 21st Century Education Shareholders' Meeting HPC Juice China Lilang HPC Holdings China Lilang HPC HOLDINGS CITIC Construction Investment Securities Tiger Pharmaceuticals Weihai Bank Jinan Industrial dividend payment Tian'an (excluding Clean Day) Kowloon Group (dividend day) Pacific Shipping (dividend day) Pacific Shipping (dividend day) (Excluding clean days) Pacific Shipping (excluding clean days) Remittance
山東新華製藥股份：2023年年報
Xinhua Pharmaceutical (000756.SZ): Pharmaceutical exports to the US and the US account for about 10% of the company's total sales
Gelonghui, April 17 | Xinhua Pharmaceutical (000756.SZ) said on the investor interactive platform that the company's pharmaceutical exports to the US, including the US, account for about 10% of the company's total sales.
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation
Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) said cefaclor capsules, a drug of its unit Shandong Zibo Xinda Pharmaceutical, passed the quality and efficacy evaluation of China's National Medi
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) plans to hold a board meeting on April 25 to approve quarterly results
Gelonghui, April 11, 丨 Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that the company will hold a board meeting at 9:30 a.m. on April 25, 2024 (Thursday) in the company conference room No. 1, Lutai Avenue, High-tech Zone, Zibo City, Shandong Province. The contents of the meeting are as follows: 1. Review and approve the unaudited performance of the company and its subsidiaries for the three months ended March 31, 2024; and 2. Any other matters, if applicable.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Wholly-owned subsidiary cefaclor capsules passed generic drug consistency evaluation
Gelonghui, April 10 | Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that recently, Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinda Pharmaceutical”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for cefaclor capsules (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. The product passed the consistent evaluation of the quality and efficacy of generic drugs.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Obtained approval notice for supplemental application for peramivir injectable drugs
Gelonghui, April 8, 丨 Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) issued an announcement. Recently, the company received the “Drug Supplement Application Approval Notice” for paramivir injection (15ml: 0.15g) approved by the State Drug Administration, and the transfer application of the product's marketing license holder was approved.
Shandong Xinhua Pharmaceutical Proposes New Auditor
Shandong Xinhua Pharmaceutical Company (HKG:0719) will replace its current auditor ShineWing Certified Public Accountants as they have served a maximum term under the Administrative Measures, accordin
Xinhua Pharmaceutical (000756.SZ): Net profit increased by 20.79% to 497 million yuan in 2023, plans to distribute 10 to 2.5 yuan
Gelonghui, March 28 | Xinhua Pharmaceutical (000756.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 8.101 billion yuan, up 7.97% year on year; net profit attributable to shareholders of listed companies was 497 million yuan, up 20.79% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 462 million yuan, up 21.94% year on year; basic income per share was 0.74 yuan; it plans to distribute 2.5 yuan (tax included) to all shareholders for every 10 shares.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) plans to pay a final dividend of 0.25 yuan per share
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) issued an announcement that it will be distributed at the end of the year ending December 31, 2023...
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced 2023 results, net profit of 496.5 million yuan, a year-on-year increase of 20.79%
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced its 2023 results, with operating revenue of about 8.1 billion yuan, an increase of 7...
SHANDONG XINHUA: Announcement for 2023 Annual Results
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) held a board meeting on March 28 to review and approve annual results
Gelonghui, March 14, 丨 Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that the company will hold a board meeting at 9:30 a.m. on March 28, 2024 (Thursday) in the company conference room 1, Lutai Avenue, High-tech Zone, Zibo City, Shandong Province, China. The contents of the meeting are as follows: 1. Review and approve the audited annual results of the company and its subsidiaries as of December 31, 2023; 2. Review the issuance of a final dividend (if any); and 3. Any other matters, if applicable.
SHANDONG XINHUA: Announcement Notice of Board Meeting
Xinhua Pharma's Ibuprofen Gets Registration Approval in China
Shandong Xinhua Pharmaceutical (HKG:0719) obtained a drug registration certificate from China's National Medical Products Administration for its ibuprofen sustained release capsules, according to a fi
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Obtained ibuprofen sustained-release capsule drug registration certificate
Gelonghui March 12丨Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) issued an announcement. Recently, Xinhua Pharmaceutical received the “Drug Registration Certificate” for ibuprofen sustained-release capsules approved and issued by the State Drug Administration. Xinhua Pharmaceutical's ibuprofen sustained-release capsules obtained a drug registration certificate in March 2024, further enriching the company's ibuprofen product line and providing patients with new antipyretic and analgesic medication options.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Obtained a notice of approval for the marketing application of prednisone chemical raw materials
Gelonghui, Feb. 28, 丨 Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) issued an announcement. Recently, the company received approval from the State Drug Administration to issue the “Notice of Approval of the Marketing Application for Chemical Ingredients” relating to the Company's prednisone (“Product”). This product has anti-inflammatory and anti-allergic effects, can inhibit connective tissue proliferation, reduce the permeability of capillary walls and cell membranes, reduce inflammatory exudation, and inhibit the formation and release of histamine and other toxic substances. In the case of severe toxic infections, this product can be used in combination with a large number of antimicrobials to provide good cooling, anti-toxic, anti-inflammatory, anti-shock and symptom relief
Analysis
Price Target
No Data
